The following guideline can be ordered through the address listed in the "Source/Publisher"-category. In cases in which you can order through the Internet we have established a hyperlink.

Bridging for Drug-Device and Biologic-Device Combination Products



Document Type:
Daft Guidance
This guidance provides recommendations to industry and FDA staff on how to approach bridging in new drug applications (NDAs) or biologics license applications (BLAs) for drug device and biologic-device single entity or copackaged combination products.

Go back

GMP Conferences by Topics